



SAFETY DATA SHEET

Product Name: Propofol Injectable Emulsion

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

Manufacturer Name And Address	Hospira, Inc. 275 North Field Drive Lake Forest, Illinois 60045 USA
Emergency Telephone	CHEMTREC: North America: 800-424-9300; International 1-703-527-3887; Australia - 61-290372994; UK - 44-870-8200418
Hospira, Inc., Non-Emergency	224 212-2000
Product Name	Propofol Injectable Emulsion
Synonyms	2,6-diisopropylphenol; 2,6-DIP

2. HAZARD(S) IDENTIFICATION

Emergency Overview	Propofol Injectable Emulsion is an oil:water mixture containing propofol, an intravenous sedative-hypnotic agent for use in the induction and maintenance of anesthesia or sedation. In the workplace, this product should be considered potentially irritating to the eyes and respiratory tract, and may cause an allergic reaction in persons with pre-existing allergies to egg or soy products. Based on clinical use, possible target organs include the nervous system, respiratory system, and cardiovascular system.
---------------------------	---

U.S. OSHA GHS Classification

Physical Hazards	Hazard Class	Hazard Category
	Not Classified	Not Classified
Health Hazards	Hazard Class	Hazard Category
	STOT – SE	3

Label Element(s)

Pictogram



Signal Word

Warning

Hazard Statement(s)

May cause drowsiness or dizziness

Precautionary Statement(s)

Prevention

Do not breathe vapor or spray
Use only outdoors or in a well-ventilated area
Wash hands thoroughly after handling

Response

Get medical attention if you feel unwell.

IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention.

IF INHALED: Remove person to fresh air and keep comfortable for breathing.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Active Ingredient Name Propofol
Chemical Formula C₁₂H₁₈O

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Propofol	1.0	2078-54-8	SL0810000

Non-hazardous ingredients include Water for Injection, egg lecithin, soybean oil and glycerin. Hazardous ingredients present at less than 1% include benzyl alcohol and sodium benzoate; sodium hydroxide is added to adjust the pH.

4. FIRST AID MEASURES

Eye Contact Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Skin Contact Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Inhalation Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Ingestion Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability None anticipated for this emulsion product.

Fire & Explosion Hazard None anticipated for this emulsion product.

Extinguishing Media As with any fire, use extinguishing media appropriate for primary cause of fire such as carbon dioxide, dry chemical extinguishing powder or foam.

Special Fire Fighting Procedures No special provisions required beyond normal firefighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal Isolate area around spill. Put on suitable protective clothing and equipment as specified by site spill control procedures. Absorb the liquid with suitable material and clean affected area with soap and water. Dispose of spill materials according to the applicable federal, state, or local regulations.

7. HANDLING AND STORAGE

Handling No special handling required for hazard control under conditions of normal product use.

Storage No special storage required for hazard control. For product protection, follow storage recommendations noted on the product case label, the primary container label, or the product insert.

Special Precautions No special precautions required for hazard control.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

Component	Exposure Limits			
	OSHA-PEL	ACGIH-TLV	AIHA WEEL	Hospira EEL
Propofol	8 hr TWA: Not Established	8 hr TWA: Not Established	8-hour TWA: Not Established	8 hr TWA: Not Established

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit
 ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.
 AIHA WEEL: Workplace Environmental Exposure Level
 EEL: Employee Exposure Limit.
 TWA: 8 hour Time Weighted Average.

Respiratory Protection

Respiratory protection is normally not needed during intended product use. However, if the generation of aerosols is likely, and engineering controls are not considered adequate to control potential airborne exposures, the use of an approved air-purifying respirator with a HEPA cartridge (N95 or equivalent) is recommended under conditions where airborne aerosol concentrations are not expected to be excessive. For uncontrolled release events, or if exposure levels are not known, provide respirators that offer a high protection factor such as a powered air purifying respirator or supplied air. A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions require respirator use. Personnel who wear respirators should be fit tested and approved for respirator use as required.

Skin Protection

If skin contact with the product formulation is likely, the use of latex or nitrile gloves is recommended.

Eye Protection

Eye protection is normally not required during intended product use. However, if eye contact is likely to occur, the use of chemical safety goggles (as a minimum) is recommended.

Engineering Controls

Engineering controls are normally not needed during the normal use of this product.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State

A sterile, non-pyrogenic white, oil-in-water emulsion for intravenous administration

Odor

Odorless or a slight phenolic odor

Odor Threshold

NA

pH

7 to 8.5

Melting point/Freezing Point

NA

Initial Boiling Point/Boiling Point Range

NA

Flash Point

NA

Evaporation Rate

NA

Flammability (solid, gas)

NA

Upper/Lower Flammability or Explosive Limits

NA

Vapor Pressure

NA

Vapor Density (Air =1)

NA

Relative Density

0.955

Solubility

Soluble in water

Partition Coefficient: n-octanol/water

6761:1 at a pH of 6 to 8.5

Auto-ignition Temperature

NA

Decomposition Temperature

NA

Viscosity

NA

10. STABILITY AND REACTIVITY

Reactivity	Not determined.
Chemical Stability	Stable under standard use and storage conditions.
Hazardous Reactions	Not determined
Conditions to Avoid	Not determined
Incompatibilities	Not determined
Hazardous Decomposition Products	Not determined. During thermal decomposition, it may be possible to generate irritating vapors and/or toxic fumes of carbon oxides (COx).
Hazardous Polymerization	Not anticipated to occur with this product.

11. TOXICOLOGICAL INFORMATION

Acute Toxicity - Not determined for the product formulation. Information for the active ingredient is as follows:

Ingredient(s)	Percent	Test Type	Route of Administration	Value	Units	Species
Propofol	100	LD50	Oral	500	mg/kg	Rat
				1100	mg/kg	Mouse
Propofol	100	LD50	Intravenous	42	mg/kg	Rat
				50	mg/kg	Mouse
				30	mg/kg	Dog

LD 50: Dosage that produces 50% mortality.

Occupational Exposure Potential	The active ingredient in this product may be absorbed via inhalation and possibly through the skin. Avoid liquid aerosol generation and skin contact.
Signs and Symptoms	None anticipated from normal handling of this product. This product may cause eye and skin irritation following inadvertent contact. During clinical use, adverse effects may include slowed heart rate, decreased blood pressure, transient apnea, nausea, rash and cough.
Aspiration Hazard	None anticipated from normal handling of this product. This product contains soybean oil. Inadvertent aspiration of vegetable oils may lead to lipid pneumonia and difficulty breathing.
Dermal Irritation/ Corrosion	None anticipated from normal handling of this product. However, inadvertent skin contact with this product may produce redness and discomfort. Based on a study in animals, the active ingredient may have some potential for skin absorption.
Ocular Irritation/ Corrosion	None anticipated from normal handling of this product. However, inadvertent contact of this product with eyes may produce irritation, redness, and discomfort.
Dermal or Respiratory Sensitization	None anticipated from normal handling of this product. However, in clinical use, rash, pruritis, and life-threatening and/or fatal anaphylactic and anaphylactoid reactions have been reported. This product may cause allergic reactions in persons with known allergies to egg or soy products.
Reproductive Effects	None anticipated from normal handling of this product. Female Wistar rats administered either 0, 10, or 15 mg/kg/day propofol intravenously from 2 weeks before pregnancy to day 7 of gestation did not show impaired fertility. Male fertility in rats was not affected in a dominant lethal study at intravenous dosages up to 15 mg/kg/day for 5 days. Reproduction studies performed in rats and rabbits at intravenous dosages of 15 mg/kg/day have revealed no evidence of harm to the fetus due to propofol.

11. TOXICOLOGICAL INFORMATION: continued

Reproductive Effects: continued	However, propofol has been shown to cause maternal deaths in rats and rabbits and decreased pup survival during the lactating period in dams treated with dosages of 15 mg/kg/day. The pharmacological activity of the drug on the dam may be responsible for the adverse effects seen in the offspring.		
Mutagenicity	Propofol was not mutagenic in the <i>in vitro</i> bacterial reverse mutation assay (Ames test) using <i>Salmonella typhimurium</i> strains TA98, TA100, TA1535, TA1537, and TA 1538. Propofol was not mutagenic in either the gene mutation/gene conversion test using <i>Saccharomyces cerevisiae</i> , or <i>in vitro</i> cytogenetic studies in Chinese hamsters. In the <i>in vivo</i> mouse micronucleus assay with Chinese Hamsters propofol administration did not produce chromosome aberrations.		
Carcinogenicity	Long-term studies in animals have not been conducted to evaluate the carcinogenic potential of propofol.		
Carcinogen Lists	IARC: Not listed	NTP: Not listed	OSHA: Not listed
Specific Target Organ Toxicity – Single Exposure	NA		
Specific Target Organ Toxicity – Repeat Exposure	Based on clinical use, possible target organs may include the nervous system, respiratory system, and the cardiovascular system.		

12. ECOLOGICAL INFORMATION

Aquatic Toxicity	Not determined for product.
Persistence/Biodegradability	Not determined for product.
Bioaccumulation	Not determined for product.
Mobility in Soil	Not determined for product.

Notes:

13. DISPOSAL CONSIDERATIONS

Waste Disposal	All waste materials must be properly characterized. Further, disposal should be performed in accordance with the federal, state or local regulatory requirements.
Container Handling and Disposal	Dispose of container and unused contents in accordance with federal, state and local regulations.

14. TRANSPORTATION INFORMATION

ADR/ADG/ DOT STATUS	Not regulated
Proper Shipping Name	NA
Hazard Class	NA
UN Number	NA
Packing Group	NA
Reportable Quantity	NA
ICAO/IATA STATUS	Not regulated
Proper Shipping Name	NA
Hazard Class	NA
UN Number	NA
Packing Group	NA
Reportable Quantity	NA
IMDG STATUS	Not regulated
Proper Shipping Name	NA
Hazard Class	NA
UN Number	NA
Packing Group	NA
Reportable Quantity	NA

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

US TSCA Status	Exempt
US CERCLA Status	Not listed
US SARA 302 Status	Not listed
US SARA 313 Status	Not listed
US RCRA Status	Not listed
US PROP 65 (Calif.)	Not listed

Notes: TSCA, Toxic Substance Control Act; CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act; SARA, Superfund Amendments and Reauthorization Act; RCRA, US EPA, Resource Conservation and Recovery Act; Prop 65, California Proposition 65

GHS/CLP Classification*

*In the EU, classification under GHS/CLP does not apply to certain substances and mixtures, such as medicinal products as defined in Directive 2001/83/EC, which are in the finished state, intended for the final user.

Hazard Class	Hazard Category	Pictogram	Signal Word	Hazard Statement
NA	NA	NA	NA	NA
Prevention	Do not breathe vapor or spray Use only outdoors or in a well-ventilated area Wash hands thoroughly after handling			
Response	Get medical attention if you feel unwell. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention. IF INHALED: Remove person to fresh air and keep comfortable for breathing.			

15. REGULATORY INFORMATION: continued

<u>EU Classification*</u>	*Medicinal products are exempt from the requirements of the EU Dangerous Preparations Directive.
Classification(s)	NA
Symbol	NA
Indication of Danger	NA
Risk Phrases	NA
Safety Phrases	S23: Do not breathe vapor/spray S24: Avoid contact with the skin S25: Avoid contact with eyes S37/39 Wear suitable gloves and eye/face protection.

16. OTHER INFORMATION

Notes:

ACGIH TLV	American Conference of Governmental Industrial Hygienists – Threshold Limit Value
CAS	Chemical Abstracts Service Number
CERCLA	US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
DOT	US Department of Transportation Regulations
EEL	Employee Exposure Limit
IATA	International Air Transport Association
LD ₅₀	Dosage producing 50% mortality
NA	Not applicable/Not available
NE	Not established
NIOSH	National Institute for Occupational Safety and Health
OSHA PEL	US Occupational Safety and Health Administration – Permissible Exposure Limit
Prop 65	California Proposition 65
RCRA	US EPA, Resource Conservation and Recovery Act
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
STEL	15-minute Short Term Exposure Limit
STOT - SE	Specific Target Organ Toxicity – Single Exposure
STOT - RE	Specific Target Organ Toxicity – Repeated Exposure
TSCA	Toxic Substance Control Act
TWA	8-hour Time Weighted Average

MSDS Coordinator: Hospira GEHS
Date Prepared: October 19, 2012
Date Revised: June 02, 2014

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.